CT-based radiomics model with machine learning for predicting primary treatment failure in diffuse large B-cell Lymphoma

• Main Authors: Raoul Santiago, Johanna Ortiz Jimenez, Reza Forghani, Nikesh Muthukrishnan, Olivier Del Corpo, Shairabi Karthigesu, Muhammad Yahya Haider, Caroline Reinhold, Sarit Assouline
• Format: Article
• Language: English
• Published: Elsevier 2021-10-01
• Series: Translational Oncology
• Subjects: Radiomics; Diffuse Large B-cell Lymphoma; Refractory; Quantitative imaging; Biomarkers
• Online Access: http://www.sciencedirect.com/science/article/pii/S1936523321001807

Biomarkers which can identify Diffuse Large B-Cell Lymphoma (DLBCL) likely to be refractory to first-line therapy are essential for selecting this population prior to therapy initiation to offer alternate therapeutic options that can improve prognosis. We tested the ability of a CT-based radiomics approach with machine learning to predict Primary Treatment Failure (PTF)-DLBCL from initial imaging evaluation. Twenty-six refractory patients were matched to 26 non-refractory patients, yielding 180 lymph nodes for analysis. Manual 3D delineation of the total node volume was performed by two independent readers to test the reproducibility. Then, 1218 hand-crafted radiomic features were extracted. The Random Forests machine learning approach was used as a classifier for constructing the prediction models. Seventy percent of the nodes were randomly assigned to a training set and the remaining 30% were assigned to an independent test set. The final model was tested on the dataset from the 2 readers, showing a mean accuracy, sensitivity and specificity of 73%, 62% and 82%, respectively, for distinguishing between refractory and non-refractory patients. The area under the receiver operating characteristic curve (AUC) was 0.83 and 0.79 for the two readers. We conclude that machine learning CT-based radiomics analysis is able to identify a priori PTF-DLBCL with a good accuracy.